Lv1
80 积分 2024-10-15 加入
Reduced-Intensity Chemotherapy with Mini-Hyper-CVD Plus Inotuzumab Ozogamicin, with or without Blinatumomab, in Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: Results from a Phase II Study
8天前
已关闭
Analysis of Patients With Monocytic and Monocytic-Like Acute Myeloid Leukemia, Including AML-M4 and AML-M5, Treated With Venetoclax Plus Azacitidine
1个月前
已完结
How I treat patients with AML using azacitidine and venetoclax
2个月前
已完结
Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML
3个月前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
3个月前
已完结
How I treat patients with AML using azacitidine and venetoclax
3个月前
已完结
Subcutaneous blinatumomab in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: post-hoc safety and activity analysis from a multicentre, single-arm, phase 1/2 trial
4个月前
已完结
Hyper-CVAD and Sequential Blinatumomab Without and With Inotuzumab in Young Adults With Newly Diagnosed Philadelphia Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia
4个月前
已完结
Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial
4个月前
已完结
Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
4个月前
已完结
皖公网安备34019202002308
